l isoleucine c6h13n o2  (Chem Impex International)

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Immunohistochemical staining of patient specimens. A-D. Representative images of immunohistochemical staining of the four proteins to illustrate typical intensity and percentage staining scores (both on a scale of 1-3). A. Excision repair cross-complementing (ERCC): intensity score 1, percentage score 3. B. ERCC2: intensity score 3, percentage score 2. C. ERCC4: intensity score 3, percentage score 2. D. Glutathione S-transferase Pi, intensity score 3, percentage score 3. Scale bar = 500 μm.

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Immunohistochemical staining, Staining

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Relationship between expression of biological markers and clinical outcomes

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Kaplan-Meier curves for patient survival. (A-D) Overall survival (OS) and progression-free survival (PFS) of patients stratified by tumor expression of excision repair cross-complementing (ERCC) 1 (A), ERCC2 (B), ERCC4 (C), and glutathione S-transferase Pi (GSTPi) (D).

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Associations between the expression of biological markers and the frequency of grade 3-4 neutropenia and anorexia

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Multivariate Cox regression analysis of factors associated with overall survival

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Modification

Journal: American Journal of Cancer Research

Article Title: Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer

doi:

Figure Lengend Snippet: Multivariate Cox regression analysis of factors associated with progression-free survival

Article Snippet: Sections were then incubated with one of the following primary antibodies for 60 min at room temperature: anti-ERCC1 (#12345, Cell Signaling Technology, Danvers, MA, USA, 1:100 dilution), anti-ERCC2 (10818-1-AP, Proteintech, Rosemont, IL, USA, 1:75), anti-ERCC4 (IHC-00263, Bethyl Laboratories, Montgomery, TX, USA, 1:300), and anti-GSTP1 (#3369, Cell Signaling Technology, 1:800).

Techniques: Modification